公开(公告)号：ZA201101477B

公开(公告)日：2012-07-25

申请号：ZA201101477

申请日：2011-02-24

Applicant: VERTEX PHARMA

Inventor： DOKOU ELENI ,  GASPARAC REHELA ,  KNEZIC DRAGUTIN ,  KLINE BILLIE ,  JURKAUSKAS VALDAS

IPC: A61K20060101

Abstract: An immediate release formulation of an active ingredient.

公开(公告)号：CA2735431A1

公开(公告)日：2010-03-11

申请号：CA2735431

申请日：2009-08-28

Applicant: VERTEX PHARMA

Inventor： DOKOU ELENI ,  GASPARAC REHELA ,  KNEZIC DRAGUTIN ,  KLINE BILLIE ,  JURKAUSKAS VALDAS

IPC: A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48

Abstract: An immediate release formulation of an active ingredient, wherein the active ingredient is a co-crystal of VX-950 and a 4-hydroxybenzoic acid.

公开(公告)号：MX387720B

公开(公告)日：2025-03-12

申请号：MX2016013301

申请日：2016-10-10

Applicant: VERTEX PHARMA

Inventor： MEDEK ALES ,  PHENIX BRIAN DEAN ,  KNEZIC DRAGUTIN ,  DOKOU ELENI ,  BRODEUR GEOFFREY GLEN ,  MCCARTY KATIE LYNN ,  BAGNOL LAURENT JEAN- CLAUDE ,  FERRIS LORI ANN ,  CHANDRAN SACHIN ,  WAGGENER SARA A

IPC: A61K45/06 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/404 ,  A61K31/47 ,  C07D209/04 ,  C07D215/00

Abstract: La presente invención presenta una composición que comprende una pluralidad de agentes terapéuticos en donde la presencia de un agente terapéutico mejora las propiedades de al menos otro agente terapéutico. En una modalidad, los agentes terapéuticos son reguladores de conductancia de transmembrana de fibrosis Quísticas (CFTR) tal como un corrector CFTR o potenciador CFTR para el tratamiento de enfermedades mediadas por el CFTR, tal como fibrosis Quística. También se describen sus métodos y kits.

公开(公告)号：CA2944140C

公开(公告)日：2022-10-04

申请号：CA2944140

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： PHENIX BRIAN DEAN ,  BAGNOL LAURENT JEAN-CLAUDE ,  BRODEUR GEOFFREY GLEN ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ANN ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE LYNN ,  MEDEK ALES ,  WAGGENER SARA A

IPC: A61K9/14 ,  A61K31/404 ,  A61K31/47 ,  A61P43/00

Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

公开(公告)号：ES2885181T3

公开(公告)日：2021-12-13

申请号：ES18173500

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： PHENIX BRIAN DEAN ,  BAGNOL LAURENT JEAN-CLAUDE ,  BRODEUR GEOFFREY GLEN ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ANN ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE LYNN ,  MEDEK ALES ,  WAGGENER SARA A

IPC: A61K45/06 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/404 ,  A61K31/47 ,  C07D209/04 ,  C07D215/00

Abstract: Una dispersión secada por pulverización que comprende (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-N-(1-(2,3- dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1H-indol-5-il)ciclopropanocarboxamida (Compuesto 1) y N-(5- hidroxi-2,4-di-terc-butil-fenil-4-oxo-1H-quinolina-3-carboxamida (Compuesto 2), en donde la dispersión secada por pulverización es sustancialmente amorfa y comprende menos de aproximadamente el 15 % de cristalinidad.

公开(公告)号：RS57476B9

公开(公告)日：2021-10-29

申请号：RSP20180880

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： PHENIX BRIAN DEAN ,  BAGNOL LAURENT JEAN-CLAUDE ,  BRODEUR GEOFFREY GLEN ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ANN ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE LYNN ,  MEDEK ALES ,  WAGGENER SARA A

IPC: A61K45/06 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/404 ,  A61K31/47 ,  C07D209/04 ,  C07D215/00

公开(公告)号：UA124567C2

公开(公告)日：2021-10-13

申请号：UAA201611464

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： PHENIX BRIAN DEAN ,  BAGNOL LAURENT JEAN-CLAUDE ,  BRODEUR GEOFFREY GLEN ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ANN ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE LYNN ,  MEDEK ALES ,  WAGGENER SARA A

Abstract: Винахідстосуєтьсяфармацевтичноїкомбінації, якамістить: першувисушенурозпиленнямдисперсіюі другувисушенурозпиленнямдисперсію, депершависушенарозпиленнямдисперсіяміститьвідприблизно 70 % мас. доприблизно 90 % мас. аморфного (R)-1-(2,2-дифторбензо[d][1,3]діоксол-5-іл)-N-(1-(2,3-дигідроксипропіл)-6-фтор-2-(1-гідрокси-2-метилпропан-2-іл)-1H-індол-5-іл)циклопропанкарбоксаміду (сполука 1) івідприблизно 10 % мас. доприблизно 30 % мас. полімеру, дедругависушенарозпиленнямдисперсіяміститьаморфний N-[2,4-біс(1,1-диметилетил)-5-гідроксифеніл]-1,4-дигідро-4-оксохінолін-3-карбоксамід (сполука 2); ідевказанафармацевтичнакомбінаціяявляєсобоютаблетку.

公开(公告)号：SG10201913575VA

公开(公告)日：2020-02-27

申请号：SG10201913575V

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： PHENIX BRIAN ,  BAGNOL LAURENT ,  BRODEUR GEOFFREY ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE ,  MEDEK ALES ,  WAGGENER SARA

Abstract: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed. Fig: None

公开(公告)号：AU2015247850B2

公开(公告)日：2019-07-18

申请号：AU2015247850

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： PHENIX BRIAN DEAN ,  BAGNOL LAURENT JEAN-CLAUDE ,  BRODEUR GEOFFREY GLEN ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ANN ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE LYNN ,  MEDEK ALES ,  WAGGENER SARA A

IPC: A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/404 ,  A61K31/47 ,  A61K45/06 ,  C07D209/04 ,  C07D215/00

Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

公开(公告)号：HK1205690A1

公开(公告)日：2015-12-24

申请号：HK15106314

申请日：2015-07-02

Applicant: VERTEX PHARMA

Inventor： DOKOU ELENI ,  JAMZAD SHAHLA ,  CAESAR JOHN P JR ,  FAWAZ MAJED ,  DAS LAURA ,  GU CHONG-HUI ,  HURTER PATRICIA NELL ,  ISRANI MEGHNA JAI ,  JOHNSTON MEGHAN M ,  KNEZIC DRAGUTIN ,  KUZMISSION ANDREW G ,  WANG HONGREN

IPC: A61K20060101

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.